Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Musk Says He Won’t Do Anything ‘That Would Somehow Be Advantageous To Tesla’

-Twitter Spaces Conversation
byBenzinga Newsdesk
November 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

-Twitter Spaces Conversation

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Ultomiris Showed Zero Relapses in Adults With Neuromyelitis Optica Spectrum Disorder With Median Treatment Duration of 73 Weeks

By Charles Gross
October 27, 4:45 AM
Results from CHAMPION-NMOSD trial demonstrated Ultomiris reduced the risk of relapse in AQP4 Ab+ NMOSD by 98.6% compared to placebo. Ultomiris also showed a lower proportion of patients experiencing clinically important worsening in Hauser Ambulatory Index score, a measure of patient mobility.

AZN